Can a smarter needle catch more prostate cancers?

NCT ID NCT06907446

Recruiting now Diagnosis Sponsor: University of California, Davis Source: ClinicalTrials.gov ↗

First seen Aug 06, 2026 · Last updated Aug 07, 2026 · Updated 1 time

Summary

This trial compares two biopsy needles used during prostate biopsies to see if one provides better tissue samples for cancer detection. The new needle is designed to collect more intact tissue per sample, which might improve the accuracy of diagnosing and grading prostate cancer. Participants will undergo a standard prostate biopsy, with samples taken using both needles to compare their performance.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Two types of biopsy needles: the SureCore needle and the standard Bard needle
What this could lead to: If the new needle provides better tissue samples, it could improve the accuracy of prostate cancer diagnosis and grading.
What could go wrong: This is a small early-stage study, and the new needle may not prove better in practice. Biopsy procedures carry risks like bleeding or infection.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATE CANCER

Contacts and locations

Locations

UC Davis Departments of Urologic Oncology
RECRUITING

Sacramento, California, 95817, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.